Preclinical testing revealed potential for QT
prolongation
A previous CCR5 antagonist (Schering C) found to
cause QT prolongation
Thorough QT study for MVC determined to be
inadequate
No significant prolongation with MVC, but control
arm was not interpretable
Attempts to resolve this issue are underway
MedDRA terms: Arrhythmia, Palpitations, Syncope,
Tachycardia
14 patients with potential ventricular
events:
MVC QD 4
(1.0%)
MVC BID
7 (1.6%)
Placebo
3 (1.4%)